Genesis CancerCare Selects PerFRACTION Software from Sun Nuclear as Network-Wide Patient QA Solution
MELBOURNE, Fla., Oct. 3, 2016 /PRNewswire-iReach/ -- Sun Nuclear Corporation announced today its PerFRACTION™ patient-specific quality assurance (QA) software has been selected for deployment by Genesis CancerCare, Australia's largest radiation oncology provider with more than 300,000 patients treated annually at 25 clinics nationwide. PerFRACTION is a module within the SunCHECK™ radiation therapy quality management platform, and is exclusively distributed in Australia and New Zealand by alphaXRT.
Photo - http://photos.prnewswire.com/prnh/20160930/414088
The PerFRACTION application works with both Varian and Elekta linear accelerators and ARIA® and MOSAIQ® oncology information systems, covering two critical patient QA phases:
– The Fraction 0™ feature performs 3D pre-treatment IMRT and VMAT QA to verify delivered dose from a linear accelerator against planned dose for each patient treatment.
– The Fraction n™ feature supports 3D in-vivo monitoring of treatment progress, allowing clinicians to accurately identify and understand the impact of set-up errors and anatomy changes on dose delivered to the patient.
Across both phases, PerFRACTION provides EPID-based measurements, ensuring independence from the delivery system. Relevant patient and machine files are automatically captured, analyzed and displayed within an intuitive user interface featuring a suite of data visualization tools. As a web-based application, PerFRACTION will be accessible by any secure networked computer within a Genesis CancerCare facility.
"We strive to deliver independent, relevant QA solutions for radiation oncology clinics focused on continually improving cancer treatment effectiveness," said Jeff Simon, Chief Executive Officer, Sun Nuclear Corporation. "Genesis CancerCare is certainly setting a standard for efficiency and integration toward this goal. They are an ideal partner for us, and we look forward to collaborating with their affiliates for years to come."
Keith Hansen, Executive Manager for Genesis CancerCare Australia, said, "PerFRACTION enables us to offer every patient the highest quality and safest level of care in Australia. With PerFRACTION monitoring the quality of our treatments, our doctors have data to demonstrate that the treatment they prescribed had in fact been delivered safely, to the highest standards and importantly on time."
Richard Neale, Managing Director of alphaXRT added, "PerFraction and SunCHECK are game-changing products and we are proud to implement and support them in Australasia. This is a significant investment by Genesis CancerCare and we are confident that patient safety and department workflows will both be enhanced by these products."
The PerFRACTION software—including new features such as 3D dose recalculation on daily CBCT—will be demonstrated in the Sun Nuclear booth (#3077) at the annual meeting of the American Society for Radiation Oncology (ASTRO). The conference runs from September 25-28, 2016, in Boston, Mass., U.S.
About Sun Nuclear Corporation
Sun Nuclear Corporation is the worldwide market leader in QA (quality assurance) and dosimetry solutions for Radiation Oncology. The company designs and manufactures medical devices and software for radiation therapy treatment delivery systems and patient prescription verification. Sun Nuclear's solutions perform radiation measurement, data collection, testing, performance assessment, and analytics for over 4,000 radiation oncology clinics worldwide. The company is a pioneer in radiation detector research and development, most notably solid state diode detectors and ionization chambers. The company holds numerous patents for groundbreaking product designs and distributes solutions directly in the US and through a network of over 60 trained distributors outside of the US.
Media Contact: Kevin O'Malley, Sun Nuclear Corporation, (608) 828 7000 x1238, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Sun Nuclear Corporation